Background. Although probiotics are being intensively studied in the US for many different pediatric endpoints, few studies have been performed in low-income countries. We sought to investigate safety of two commonly used probiotics in Bangladeshi infants.
Methods. Infants age 4 to 12 weeks were randomized to one month of a combination of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum infantis on three different schedules: daily, weekly, or biweekly (every two weeks) or to non-probiotic control. Infants were followed for three months with mothers reporting daily health status. We compared gastrointestinal (GI) and lower respiratory (LR) symptom rates (days with symptoms/total follow-up days) across arms and assessed hospitalizations; tests for trend were also performed.
Results. As of April 2014, 123 infants have been randomized and had health data reported with a mean of 8.1 weeks of follow-up. Overall GI symptoms were rare; cough and congestion were the most common LR symptoms (table) . Although some differences between arms were statistically different, no clear patterns in relation to dosing frequency were seen. 7 infants (3 from biweekly arm, 2 from weekly arm, and 2 from daily arm) were hospitalized for a total of 9 occasions-5 for pneumonia and 4 for diarrhea-and recovered fully; these hospitalizations were neither temporally related to probiotic use nor considered probiotic-related by the DSMB. No allergic responses or other reactions were observed after probiotic administration. 
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